RBC Capital analyst Luca Issi maintained a Hold rating on Moderna (MRNA – Research Report) on November 25 and set a price target of $50.00. The ...

On Tuesday, Moderna Inc (MRNA) stock saw a decline, ending the day at $42.05 which represents a decrease of $-1.61 or -3.69% from the prior close of $43.66. The stock opened at $43.13 and touched a ...

We recently compiled a list of the 10 Worst Performing Healthcare Stocks in 2024. In this article, we are going to take a ...

Following the unexpected death of the Czech musician Vojtěch Havel last month, Miloš Hroch offers a guide to the ...

This segment is sponsored by the Altoona Center for Clinical Research ALTOONA, Pa. (WTAJ) — A Clinical Trial to Evaluate an ...

As the cold sets in and we are spending most of our time indoors with family and friends, we have to pay attention because a ...

JPMorgan lowered the firm’s price target on Moderna (MRNA) to $45 from $59 and keeps an Underweight rating on the shares. The firm updated ...

The Nasdaq-100 index tracks the largest 100 non-financial companies on the Nasdaq stock exchange. Although it's not a part of ...

We recently compiled a list of the 10 Oversold Healthcare Stocks To Invest In. In this article, we are going to take a look ...

The pharmaceutical industry operates under a complex regulatory landscape, balancing government oversight with self-imposed ...

Moderna stock is undervalued with a $97 price target, strong COVID-19 revenue, promising pipeline, and long-term growth. Read ...

As the new administration prepares to take over, there will be no time to waste in tackling enormous challenges in a region ...